Digitisation | April 01, 2022
Arzeda closes US$33 million Series B funding
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
The fund has already invested in seven companies including Medikabazaar, THB, Impact Guru, Stanplus, Ekincare, Qure.ai and HealthifyMe
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
Subscribe To Our Newsletter & Stay Updated
